
Eisai and Biogen are now making another attempt to tackle Alzheimer's disease, initiating a "rolling submission" process at the US Food and Drug Administration (FDA) of the drug lecanemab, the companies inform in a press release.
Like the company's other Alzheimer's drug, Aduhelm, which was FDA approved earlier this year, lecanemab is an antibody targeting the amyloid beta protein. In theory, by breaking down the protein plaques, the antibody should slow down the progression of the disease.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app